Amicus Therapeutics

Amicus Therapeutics

A biotechnology company developing therapies to cure rare diseases

Amicus Therapeutics is a publicly listed biotechnology company focused on the discovery, development, and delivery of treatments for rare metabolic diseases. Headquartered in New Jersey, the company also operates officers internationally. They include the UK, Canada, Japan, Germany, France, Italy, The Netherlands, Spain, and Australia.

Products

Medication for Fabry disease

Amicus' developments include one commercialized medication for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and several gene therapy pipeline and growth platform for lysosomal storage disorders, including Batten Disease, Neimann-Pick Type C, Wolman Disease, and Tay Sachs.

In August 2018, the US FDA approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare and sometime fatal condition in which accumulation of fat damages several organs. It is a long-term treatment for adult patients with specific genetic mutations, which account for an estimated 35 to 50% of diagnosed cases globally. Chemically known as migalastat, the drug has also been approved in Europe, Japan, Australia, and Canada.

Medication for Pompe disease

The company's investigational therapy, AT-GAA, for Pompe disease, an inherited Lysosomal Storage (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), completed a Phase 2 safety and pharmacokinetics study in 2013.

Gene Therapy for Batten disease

Amicus is also conducting multiple Phase 1/2 studies for their CLN6 gene therapy to treat Batten disease, a broad class of rare, fatal, inherited disorders of the nervous system known as neuronal ceroid lipofuscinoses (NCLs).

Funding

Series A

On July 25, 2002 Amicus Therapeutics completed their series A funding round with $2 million in funding from CHL Medical Partners.

Series B

On May 13, 2004 Amicus Therapeutics completed their series B funding round with $31 million in funding from Canaan Partners (lead investor), Radius Venture Partners, New Enterprise Associates, Frazier Healthcare Partners, and CHL Medical Partners.

Series C

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners.

Timeline

March 30, 2019

Series B funding round

On May 13, 2004 Amicus Therapeutics completed their series B funding round with $31 million in funding from Canaan Partners (lead investor), Radius Venture Partners, New Enterprise Associates, Frazier Healthcare Partners, and CHL Medical Partners.

March 30, 2019

Series C funding round

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners.

July 25, 2002

Series A funding round

On July 25, 2002 Amicus Therapeutics completed their series A funding round with $2 million in funding from CHL Medical Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Amicus Therapeutics funding round, July 2012
18,582,360
July 30, 2012
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Adriane Schilling

Employee

Allan Powe

Employee

Anne-Lise Wohlers

Employee

Bradley L. Campbell

President & COO

Christopher Holterhoff

Employee

connor ratycz

Employee

Daphne Quimi

Senior VP, Finance and Administration

David Clark

Chief People Officer

David Palling

Employee

Deyun Wang

Employee

Edward (Ed) Kawamura

Employee

Ellen S. Rosenberg

General Counsel & Corporate Secretary

Jack Kenney

Employee

Jay A. Barth

Chief Medical Officer

Jeffrey P. Castelli

Chief Portfolio Officer

Jennifer Wilson

Employee

John F. Crowley

Chairman & CEO

Kimberly Siu

Employee

Martin Warner

Employee

Nick Peist

Employee

shankar satchit

Employee

William D. Baird, III

CFO

Further reading

Title
Author
Link
Type
Date

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Robin Respaut

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
WuXi Biologics
Invalid Date
www.prnewswire.com:443
SHANGHAI and CRANBURY, N.J., Feb. 11, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.